EDIT
Price
$2.83
Change
+$0.13 (+4.81%)
Updated
Sep 21 closing price
Capitalization
414.67M
49 days until earnings call
Intraday BUY SELL Signals
SLS
Price
$11.37
Change
-$0.12 (-1.04%)
Updated
Sep 21 closing price
Capitalization
2.32B
58 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs SLS

EDIT vs SLS Comparison Chart in %
View a ticker or compare two or three
VS
EDIT vs. SLS commentary
Sep 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and SLS is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLS($2.32B) has a higher market cap than EDIT($415M). SLS YTD gains are higher at: 204.775 vs. EDIT (31.707). SLS has higher annual earnings (EBITDA): -35.22M vs. EDIT (-67.46M). EDIT has more cash in the bank: 212M vs. SLS (138M). SLS has less debt than EDIT: SLS (737K) vs EDIT (15.5M). EDIT has higher revenues than SLS: EDIT (47M) vs SLS (0).
EDITSLSEDIT / SLS
Capitalization415M2.32B18%
EBITDA-67.46M-35.22M192%
Gain YTD31.707204.77515%
P/E RatioN/AN/A-
Revenue47M0-
Total Cash212M138M154%
Total Debt15.5M737K2,103%
FUNDAMENTALS RATINGS
EDIT vs SLS: Fundamental Ratings
EDIT
SLS
OUTLOOK RATING
1..100
5078
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6034
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (35) in the Biotechnology industry is in the same range as SLS (61). This means that EDIT’s stock grew similarly to SLS’s over the last 12 months.

SLS's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as EDIT (100). This means that SLS’s stock grew similarly to EDIT’s over the last 12 months.

SLS's SMR Rating (97) in the Biotechnology industry is in the same range as EDIT (99). This means that SLS’s stock grew similarly to EDIT’s over the last 12 months.

SLS's Price Growth Rating (34) in the Biotechnology industry is in the same range as EDIT (60). This means that SLS’s stock grew similarly to EDIT’s over the last 12 months.

SLS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that SLS’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITSLS
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 14 days ago
86%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
83%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
89%
COMPARISON
Comparison
Sep 22, 2026
Stock price -- (EDIT: $2.70 vs. SLS: $11.49)
Brand notoriety: EDIT and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 848% vs. SLS: 232%
Market capitalization -- EDIT: $414.67M vs. SLS: $2.32B
EDIT [@Biotechnology] is valued at $414.67M. SLS’s [@Biotechnology] market capitalization is $2.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $128.84B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while SLS’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, both EDIT and SLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while SLS’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 6 bearish.
  • SLS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both EDIT and SLS are a bad buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а 0.00% price change this week, while SLS (@Biotechnology) price change was -0.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -8.11%, and the average quarterly price growth was +5.22%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

SLS is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-2.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
SLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGJIX83.050.40
+0.48%
Calvert US Large Cap Growth Rspnb Idx I
LCLAX59.390.16
+0.27%
ClearBridge Select A
DSHZX13.870.01
+0.07%
Brinker Capital Destinations Shelter Z
PAMCX90.91-0.03
-0.03%
T. Rowe Price Mid-Cap Growth Adv
IGHAX13.01-0.06
-0.46%
Voya Global High Dividend Low Vol Port A